Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $256.5 million.

  • Revolution Medicines' Accumulated Expenses rose 22881.13% to $256.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.5 million, marking a year-over-year increase of 22881.13%. This contributed to the annual value of $96.6 million for FY2024, which is 2934.77% up from last year.
  • As of Q3 2025, Revolution Medicines' Accumulated Expenses stood at $256.5 million, which was up 22881.13% from $245.1 million recorded in Q2 2025.
  • Revolution Medicines' Accumulated Expenses' 5-year high stood at $256.5 million during Q3 2025, with a 5-year trough of $20.4 million in Q1 2021.
  • Over the past 5 years, Revolution Medicines' median Accumulated Expenses value was $42.6 million (recorded in 2023), while the average stood at $68.7 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 622.27% in 2022, then soared by 26211.2% in 2025.
  • Revolution Medicines' Accumulated Expenses (Quarter) stood at $27.7 million in 2021, then rose by 6.22% to $29.4 million in 2022, then soared by 153.66% to $74.7 million in 2023, then grew by 29.35% to $96.6 million in 2024, then skyrocketed by 165.5% to $256.5 million in 2025.
  • Its Accumulated Expenses stands at $256.5 million for Q3 2025, versus $245.1 million for Q2 2025 and $98.1 million for Q1 2025.